Filter By:

Completed

CTN 119: Abacavir plus Amprenavir versus Nelfinavir

A Comparison of a Four-drug Regimen Comprised of 141W94, Abacavir (1592U89), and Combivir with a Three-drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naïve, HIV-Infected Subjects. (Protocol 528/270 [NZTA4002])

Learn More

Completed

CTN 118: Once Daily ADV plus ddI plus 3TC plus NVP (QD Study)

A Comparative Study of the Antiviral Effect of a Two or Three Times Daily Triple-Drug Regimen (Indinavir, Nelfinavir or Saquinavir [SGC], Lamivudine plus Zidovudine or Stavudine) against a Once Daily Regimen including Adefovir, Didanosine, Lamivudine and Nevirapine: Trial results

Learn More

Completed

CTN 115: 141W94 (Amprenavir) versus Indinavir

A Phase III Trial to Compare the Safety and Antiviral Efficacy of 141W94 with Indinavir in Combination with Standard Nucleoside Reverse Transcriptase Inhibitor (NRTI) Therapy in NRTI-Experienced, Protease Inhibitor (PI)-Naïve, HIV-1 Infected Patients. (Protocol PROA/B3006 [569/050]): Trial results

Learn More

Completed

CTN 114: SCH 56592 versus Fluconazole for Thrush

A Multicentre, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients: Trial results

Learn More
Canadian Association for HIV Research

CTN Trials have been approved by the Community Advisory Committee of the Canadian HIV Trials Network and the Network’s Scientific Review Committee, or other national peer-review panels such as those at the Canadian Institutes of Health Research and the U.S. National Institutes of Health. CTNPT studies are small-scale investigations designed to determine the feasibility of research concepts, and do not all go through the regular CTN clinical trial review process. For information on the benefits and risks of participating in HIV clinical trials, call CATIE toll-free at 1-800-263-1638.